Entrada Therapeutics To Announce Topline Results From Cohort 1 Of Double-Blind, Placebo-Controlled, Multiple Ascending Dose Portion Of Phase 1/2 ELEVATE-44-201 Clinical Study Of ENTR-601-44 On May 7

Benzinga Newsdesk www.benzinga.com Neutral 86.5%

Neg 0% Neu 86.5% Pos 0%

Comments

No comments yet. Be the first!